Will Europe discourage the launch of new Alzheimer's drugs? The pharmaceutical industry is under pressure to deliver new therapies for Alzheimer's disease, but the regulatory bureaucracy in Europe coupled with the demand for lower-priced medicines continues to hinder efforts in innovation

In September 2012, the first global World Alzheimer's month was held, representing an international campaign to raise awareness and challenge stigma concerning the disease. Alzheimer's disease has a heavy social [...]